Skip to main
NBY
NBY logo

NovaBay Pharmaceuticals (NBY) Stock Forecast & Price Target

NovaBay Pharmaceuticals (NBY) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBay Pharmaceuticals Inc. has received a significant infusion of capital with an increased acquisition offer of $11.5 million, reflecting external validation of its business prospects. The company's revenue reached $2.4 million, which demonstrates a stable financial performance amid market expectations, although it fell slightly short of both internal estimates and consensus projections. Furthermore, despite acknowledging inherent valuation risks, there is confidence that the balance of risks and opportunities positions NovaBay favorably for future growth in the eye-care and related product sectors.

Bears say

NovaBay Pharmaceuticals Inc. reported a net loss of $2.2 million, translating to an earnings per share (EPS) of $(0.60), which significantly exceeded both internal estimates of $(0.28) and consensus expectations of $(0.30). The company faces multiple risks that could adversely impact its financial outlook, including potential failures in demonstrating safety and efficacy for its product candidates, difficulty in gaining regulatory approval, and challenges related to consumer acceptance and competition. Additionally, the lack of adjusted historical financials complicates the comparability of current results with those from previous periods, further contributing to uncertainty regarding the company’s performance.

NovaBay Pharmaceuticals (NBY) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBay Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBay Pharmaceuticals (NBY) Forecast

Analysts have given NovaBay Pharmaceuticals (NBY) a Strong Buy based on their latest research and market trends.

According to 4 analysts, NovaBay Pharmaceuticals (NBY) has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBay Pharmaceuticals (NBY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.